AAV's and uses thereof
The invention in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the invention relates to gene transfer methods using the recombinant adeno-associate viruses. In some aspects, the invention relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
1. A composition comprising an isolated adeno-associated virus (AAV) vector wherein the isolated adeno-associated virus (AAV) vector comprises
(i) the isolated adeno-associated virus (AAV) capsid protein of the amino acid sequence SEQ ID NO: 91; and
(ii) a nucleic acid encoding a heterologous transgene.
2. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
3. The composition of claim 1 , wherein the heterologous transgene comprises a tissue-specific promoter operably linked to a coding sequence.
4. The composition of claim 3 , wherein the coding sequence encodes a therapeutic protein.
5. The composition of claim 4 , wherein the therapeutic protein is aromatic amino acid decarboxylase (AADC).